Highlights

  • Genetic Signatures has asked BCAL Diagnostics to clarify details around its reported 18.46% relevant interest in GSS.
  • GSS said its share register does not show an increase in BDX’s direct shareholding.
  • The company has sought clarification regarding shares held by Lawn Views Pty Ltd and any association with BDX.
  • BDX has also issued a section 249D notice seeking the removal of Chair Mike Aicher and appointment of two new directors.
  • Genetic Signatures is reviewing the notice and will convene a general meeting if it determines the notice is valid.

Genetic Signatures Limited (ASX:GSS) has become the subject of a Shareholder and governance development after raising questions over the shareholding position of BCAL Diagnostics Ltd and receiving a formal request for a shareholder meeting to consider changes to its board.

Genetic Signatures shares were trading flat at AUD 0.090 during the morning Trading session on 3 September 2026. Based on the supplied market information, the stock remained down 67.86% over the past year.

The company’s 3 September announcement centres on two related matters: clarification of BCAL Diagnostics’ reported interest in Genetic Signatures and a section 249D notice seeking the removal of current Chair Mike Aicher and the appointment of Susan Margaret Forrester and John Robert Melki as directors.

Shareholding Under Review

The issue follows a Form 604 lodged by BCAL Diagnostics on 26 August 2026.

In that notice, BDX reported that its relevant interest in Genetic Signatures had increased from 10.2% to 18.46% after the purported Acquisition of 18.75 million GSS shares.

BCAL Diagnostics also stated in an ASX announcement dated 26 August that it had acquired the shares for AUD 1.5 million, equating to AUD 0.08 per share in cash.

Genetic Signatures has since reviewed its own share register and said it has not identified a corresponding increase in BDX’s direct shareholding.

Instead, the company said the same number of shares referred to in BDX’s announcement are recorded on the GSS register as being held by Lawn Views Pty Ltd <Angela Williams Family A/C>.

That discrepancy has prompted Genetic Signatures to seek further clarification directly from BDX.

Questions Put to BDX

Genetic Signatures has asked BCAL Diagnostics to confirm whether it owns the 18.75 million shares referred to in its 26 August announcement.

The company has also asked whether any of BDX’s associates hold shares in Genetic Signatures and whether any relevant agreement exists between BDX and Lawn Views or any of its associates for the purposes of section 671B(3)(d)(iii) of the Corporations Act 2001.

According to the announcement, Lawn Views’ address on the GSS share register is Level 29, 55 Collins Street, which is also the registered office of Kidder Williams Limited.

Genetic Signatures also said its review of the ASIC companies register indicates that Lawn Views’ sole director and shareholder is Angela Kate Williams.

At this stage, the company has not stated that any breach or improper conduct has occurred. Its announcement is limited to seeking clarification about the ownership and association arrangements surrounding the shares.

Board Changes Proposed

Alongside the shareholding questions, Genetic Signatures has received a formal request from BDX under section 249D of the Corporations Act.

The notice calls on GSS directors to convene a general meeting of shareholders to consider three resolutions.

One resolution seeks the removal of Michael Aicher, the company’s current Chair, as a director.

The other two resolutions propose the appointment of Susan Margaret Forrester and John Robert Melki as directors of Genetic Signatures.

A section 249D notice allows eligible shareholders to require a company to call and arrange a general meeting, subject to the statutory requirements being satisfied.

Genetic Signatures said it is currently considering the notice and assessing its validity.

If the company determines that the notice is valid, it said it will comply with its obligations under the Corporations Act and take the necessary steps to convene a general meeting.

Governance Now in Focus

For Genetic Signatures (ASX:GSS), the development shifts near-term attention toward shareholder structure and board composition rather than an operational or financial update.

The immediate questions centre on the status of BDX’s reported relevant interest, the relationship, if any, between BDX and other holders, and whether the proposed board resolutions proceed to a shareholder vote.

The company has not yet provided a timetable for a general meeting, as that depends on its review of the section 249D notice.

Similarly, no further conclusion has been reached regarding BDX’s shareholding disclosure. Genetic Signatures has simply stated that its register does not reflect the direct increase in BDX holdings described in the earlier Form 604 and has asked for clarification.

Company Operations

Away from the governance issue, Genetic Signatures is a molecular diagnostics company focused on the development and commercialisation of its proprietary 3base® platform technology.

The company designs and manufactures real-time Polymerase Chain Reaction-based diagnostic products under the EasyScreen™ brand.

Its technology is intended for high-volume hospital and pathology laboratories undertaking infectious disease screening, with the platform designed to allow testing across a broad range of infectious pathogens.

This operating Business remains unchanged by the 3 September announcement, which deals specifically with shareholder disclosure and proposed changes to the board.

What Investors May Be Watching

Investors may now focus on how BCAL Diagnostics responds to Genetic Signatures’ questions regarding the 18.75 million shares and whether GSS receives sufficient clarification on the reported increase in relevant interest.

Attention may also remain on the company’s assessment of the section 249D notice and whether a shareholder meeting is ultimately convened to vote on the proposed removal of Mike Aicher and the proposed appointments of Susan Forrester and John Melki.

Until those matters progress, the key near-term developments are procedural and governance-related rather than operational.